Sign inCreate account

Report workspace tools

NCT07318584NOT_YET_RECRUITINGanonymous

Cefotetan Therapy for Escherichia Coli Bacteremia and Genitourinary Infections: a Prospective Phase II Pilot Study

Sponsor

Source record

Oregon Health and Science University

Phase

Source record

PHASE2

Modality

AI-normalized

small molecule

Target

AI-normalized

Cefotetan, Carbapenems, Beta Lactam Antibiotics

Indication / condition

AI-normalized

E Coli Infection

Intervention

Source record

Cefotetan, Carbapenems, Beta Lactam Antibiotics

Source & freshness

Source record

NCT ID

NCT07318584

Original source

ClinicalTrials.gov

Source last updated

Jan 06, 2026

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT07318584

Title

Cefotetan Therapy for Escherichia Coli Bacteremia and Genitourinary Infections: a Prospective Phase II Pilot Study

Sponsor

Oregon Health and Science University

Status

NOT_YET_RECRUITING

Phase

PHASE2

Condition raw

E Coli Infection, ESBL Producing E.Coli

Condition normalized

E Coli Infection, ESBL Producing E.Coli

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Cefotetan, Carbapenems, Beta Lactam Antibiotics

Target normalized

Cefotetan, Carbapenems, Beta Lactam Antibiotics

Interventions

Cefotetan, Carbapenems, Beta Lactam Antibiotics

Public preview

Source record

This pilot study will compare clinical outcomes among patients treated with cefotetan versus standard of care antibiotics for bacteremia or genitourinary infections caused by E. coli. It will also measure cefotetan minimum inhibitory concentration (MIC) distributions and cefotetan trough serum concentrations.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Cefotetan Therapy for Escherichia Coli Bacteremia and Genitourinary Infections: a Prospective Phase II Pilot Study

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT07318584

Status

NOT_YET_RECRUITING

Phase

PHASE2

Sponsor

Oregon Health and Science University

Executive brief

Investment-Ready Snapshot

This pilot study will compare clinical outcomes among patients treated with cefotetan versus standard of care antibiotics for bacteremia or genitourinary infections caused by E. coli. It will also measure cefotetan minimum inhibitory concentration (MIC) distributions and cefotetan trough serum concentrations.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJan 06, 2026
Internal syncJun 11, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT07318584

Indication

E Coli Infection

Modality

small molecule

Target

Cefotetan, Carbapenems, Beta Lactam Antibiotics

Intervention

Cefotetan, Carbapenems, Beta Lactam Antibiotics

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.